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AP-1FRA1 belongs, together with c-Fos and FosB, to the family of Fos proteins that form with members of the ATF
and Jun family the transcription factor AP-1 (activator protein 1). Previously we showed that c-Fos protects
mouse embryonic ﬁbroblasts against the cytotoxic effects of ultraviolet (UV) light by induction of the endo-
nuclease XPF, leading to enhanced nucleotide excision repair (NER) activity. Here, we analyzed the regulation
of FRA1 in glioma cells treated with the anticancer drug nimustine (ACNU) and its role in ACNU-induced
toxicity. We show that FRA1 is upregulated in glioblastoma cells following ACNU onmRNA and protein levels.
Knockdown of FRA1 by either siRNA or shRNA clearly sensitized glioma cells towards ACNU-induced cell
death. Despite decreased AP-1 binding activity upon FRA1 knockdown, this effect is independent on regula-
tion of the AP-1 target genes fasL, ercc1 and xpf. In addition, FRA1 knockdown does not affect DNA repair
capacity. However, lack of FRA1 attenuated the ACNU-induced phosphorylation of CHK1 and led to a reduced
arrest of cells in G2/M and, thereby, presumably leads to enhanced cell death in the subsequent cell cycle.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The cellular genome is permanently attacked by endogenous and
exogenous DNA damaging insults. To maintain genomic integrity,
DNA repair mechanisms have evolved [1]. DNA repair is however
not only beneﬁcial for the cell; it can also endanger the integrity of
the genome itself. Thus, DNA repair nucleases may lead, via incision
of the DNA, to DNA single-strand breaks (SSBs). If not processed
properly, these breaks can be converted into lethal DNA double-
strand breaks (DSBs) during replication. Therefore, these enzymes
have to be tightly regulated.
An important factor in transcriptional regulation of DNA repair
genes is the dimeric transcription factor AP-1 (activator protein 1),
which consists of different proteins belonging to the Fos, Jun or ATF
family [2,3]. AP-1 has been shown to stimulate a broad spectrum of
genes harbouring AP-1 sites in the promoter and thereby regulates
different cellular mechanisms like apoptosis and proliferation [4]. In
addition, AP-1 complexes consisting of c-Fos are involved in the reg-
ulation of several DNA repair genes like trex1, xpf and xpg and thereby
stimulate DNA repair activity and protect from genotoxin-induced
cell death [5-7]. Given a key role for c-Fos in genotoxic defense, the-related antigen 1; DSB, DNA
NU, nimustine, (1-(4-amino-2-
ourea hydrochloride
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rights reserved.question arises whether other members of the c-Fos family also
play a role in protection against genotoxic stress. Besides c-Fos, the
Fos-family comprises FosB, FRA1 and FRA2. In contrast to c-Fos and
FosB, FRA1 has no transactivation domain and thereby its transcrip-
tional regulatory activity is entirely dependent on its binding partner.
FRA1 is overexpressed in several types of tumors like breast can-
cer [8,9] and regulates proliferation and invasiveness [10]. In addition,
FRA1 has been shown to play a role in the maintenance/progression
of malignant gliomas [11]. In a study performed with glioblastoma
cells, it was shown that FRA1 rather mediates sensitivity than protec-
tion against the anticancer drug cisplatin [12]. Thus, knockdown of
FRA1 resulted in decreased cisplatin-induced apoptosis, which was
explained by a reduced S-phase arrest through modulation of the
CHK1–Cdk2 pathway. However cisplatin is not used routinely in the
treatment of gliomas.
Another anticancer drug leading, similar to cisplatin, to the formation
of DNA crosslinks is the chloroethylating agent nimustine (1-[4-amino-
2-methyl-5-pyrimidinyl] methyl-3-[2-chloroethyl]-3-nitrosourea hy-
drochloride, ACNU). ACNU belongs to the nitrosureas (other clinical
used drugs of this group are BCNU, CCNU and fotesmustine) and is
used as 2nd line anticancer agent in the treatment of glioblastoma.
Here we asked the question of whether FRA1 modulates the sensitivity
of glioblastoma cells to ACNU. We observed a protective effect of FRA1
on ACNU-induced cell death. This effect is most likely independent of
regulation of DNA repair genes and genes involved in apoptosis; it likely
rests on the effect of FRA1 on cell cycle progression. The data suggest
FRA1 as a factor of drug resistance in glioma and possible also other
tumor groups.
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2.1. Cell lines and anticancer drug treatment
The glioma cell lines LN229, U87, and U138 were described previ-
ously [13]. The cells were grown in Dulbecco's minimal essential
medium (DMEM) containing 10% fetal bovine serum (FBS), in 7%
CO2 at 37 °C.
2.2. Preparation of cell extracts and Western blot analysis
Whole cell extracts and nuclear cell extracts were prepared as de-
scribedpreviously [14]. Samples of 25 μg protein extractwere separated
by 10% SDS-PAGE and electro-blotted onto nitrocellulose membranes,
which were then incubated with speciﬁc antibodies. Polyclonal anti-
bodies raised against FRA1 (N17 and sc-605, Santa Cruz Biotechnology),
ERCC1 (rwo 18 [15]), p-cJun (3270, Cell Signaling), cJun (9165, Cell
Signaling), p-CHK1 (2341S, Cell Signaling), CHK1 (2345, Cell Signaling)
and monoclonal antibodies raised against γH2AXSer139 (JBW301,
Millipore), ß-Actin (C4, Santa Cruz Biotechnology), FasL (G247-4, BD
Pharmingen), XPF (ab-5 clone 51, NeoMarkers/ThermoScientiﬁc), and
XPG (8H7, Santa Cruz Biotechnology) were diluted 1:500–1:2000 in
5% non-fat dry milk and 0.2% Tween/PBS and incubated overnight at
4 °C. The protein–antibody complexes were visualized by ECL reagent
(GE Health care). Quantiﬁcation of signal intensity was performed by
use of the Multianalyst Software and the Gel Doc 1000 system from
Biorad. Signal intensity of ß-Actin, which is not regulated served as
loading control. For quantiﬁcation, the expression of the analyzed pro-
teins was normalized with ß-Actin and the untreated control was set
to one.
2.3. Preparation of RNA, RT-PCR and real-time RT-PCR
Total RNAwas isolated using the RNA II Isolation Kit fromMachery
and Nagel. One μg RNA was transcribed into cDNA by Superscript II
(Invitrogen) in a volume of 50 μl and 3 μl was subjected to RT-PCR. RT-
PCRwas performed by the use of speciﬁc primers (MWGBiotechnology)
and Red-Taq Ready Mix (Sigma-Aldrich). The PCR program used was:
1.5 min 94 °C, [(denaturation: 45 s, 94 °C; annealing: 1 min 56–62 °C;
elongation: 1 min, 72 °C) 25–30 cycles], 10 min 72 °C. Real-time RT-
PCR was performed using the LightCycler FastStart DNA Master SYBR
Green I Kit (Roche Diagnostics) and the light cycler of Roche Diagnostics.
2.4. Cloning and transfection
To generate a FRA1-shRNA vector, a 60mer hairpin-nucleotide con-
taining the FRA1 siRNA sequence CACCATGAGTGGCAGTCAG and the
corresponding antisense sequence was cloned into the Bgl II/Hind III
restriction sites of the pSUPER.basic vector (Oligo Engine). For stable
transfection, 3×105 LN229 cells were seeded per 6-cm dish. One day
later, cells were transfected with 1 μg of pSuper-FRA1-shRNA vector or
the empty pSuper vector together with 0.1 μg pSV2neo plasmid for
selection, by use of Effectene reagent as described by the manufacturer
(Qiagen). For transient down-regulation of FRA1, 20 nM siRNA speciﬁc
for FRA1 (5′-CACCATGAGTGGCAGTCAG-3′) or 20 nM non-silencing
siRNA (AllStar neg. control siRNA, Qiagen) was transfected in LN229
cells by using Lipofectamin RNAi MAX reagent as described by the
manufacturer (Invitrogen). Experiments were performed 24 h after
transfection.
2.5. Single cell gel electrophoresis (SCGE, comet assay)
For the alkaline comet assay, exponentially growing cells were
pulse-treated for 1 h with 50 μM ACNU and, after the indicated time
periods, trypsinized and washed with ice-cold PBS. Alkaline cell
lyses and electrophoresis were essentially performed as describedpreviously [16]. For the modiﬁed comet assay cells were initially
pulse-treated for 1 h with 25 μM ACNU, trypsinized after indicated
time points and washed with ice-cold PBS. After adjustment to a
cell concentration of 106 cells/ml, cells were irradiated by 8 Gy IR.
Alkaline cell lyses and electrophoresis was essentially performed as
described previously [16].
2.6. Determination of apoptosis and cell cycle distribution
For monitoring drug-induced apoptosis and cell cycle distribution,
ethanol-ﬁxed cells were treated with DNAse free RNAse and stained
with propidium iodide (PI). The Sub-G1, G1, S and G2 fraction was de-
termined by ﬂow cytometry. The protocol was described previously
[17,18]. Experiments were repeated at least three times, mean
values±SD are shown and data were statistically analyzed using
Student's t test.
2.7. Preparation of nuclear extracts and EMSA
Nuclear cell extractswere prepared and subjected to electromobility
shift assay (EMSA) or Western blot analysis as described previously
[14]. The sequence of the oligonucleotides speciﬁc for the AP-1 binding
site of the mmp1 promoter was 5′-AGTGGTGACTCATCACT-3′. For
supershift analysis, 2 μg of the speciﬁc antibodywas added and themix-
ture was additionally incubated for 1 h at 4 °C.
3. Results
3.1. Expression of FRA1 is induced following ACNU treatment
The expression of FRA1 was analyzed upon exposure of LN229 glio-
blastoma cells to the chloroethylating anticancer drug ACNU. A signiﬁ-
cant induction of fra1 mRNA was observed by semi-quantitative real-
time RT-PCR using primers located in the coding region of the gene. An
increased expression of fra1 mRNA was observed 8–24 h after exposure
of LN229 cells to 25 μM ACNU (Fig. 1A). To identify the mechanism re-
sponsible for the increase in fra1 mRNA level upon ACNU treatment,
mRNA de novo synthesis was determined. To this end, LN229 cells
were exposed to ACNU in the presence or absence of the transcription-
blocking agent actinomycin D (Fig. 1B). Treatment of LN229 cells with
the inhibitor for 7 h reduced the basal expression of fra1mRNA, indicat-
ing its high instability. In addition, treatment with actinomycin D also
abrogated the ACNU-triggered induction of fra1 mRNA, which suggests
that the observed accumulation of fra mRNA is mainly dependent on
RNA de novo synthesis. To analyze whether the increased expression of
FRA1 mRNA leads to an increased protein level, the amount of FRA1
protein was studied by Western blot analysis. As shown in Fig. 1C, a
strong time-dependent accumulation of FRA1 protein was determined
in whole cell extracts. Increase in FRA1 protein followed the mRNA
upregulation, starting 16 h after ACNU exposure. Besides transcrip-
tional regulation, also post-translational modiﬁcations by members of
the mitogen-activated protein kinase (MAPK)-cascade are important
for expression of FRA1. Since only nuclear FRA1 bound to its binding
partner c-Jun represents the active AP-1 complex, we additionally
analyzed the expression of nuclear FRA1 and c-Jun protein (Fig. 1D).
Whereas the overall amount of c-Jun was changed only slightly, a strong
nuclear accumulation of FRA1 was observed, starting 8 to 16 h after
ACNU exposure. This accumulation paralleled the activation of c-Jun
by phosphorylation, indicating a possible interaction between both
proteins, forming an active AP-1 complex.
To analyze the impact of the different MAPK on ACNU-induced
FRA1 expression, we utilized different kinase-speciﬁc inhibitors,
which were added to the medium 1 h prior to ACNU exposure. As
shown in Fig. 1E, inhibition of p38K by SB203580 and inhibition of
ERK1/2 activity using U0126 (an inhibitor of the upstream MEK1/2;
both panels) resulted in signiﬁcant reduction of ACNU-induced
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Fig. 1. ACNU-mediated induction of FRA1. (A) LN229 glioblastoma cells were exposed to
25 μM ACNU. At different time points after exposure, total RNA was isolated and semi-
quantitative RT-PCR was performed using fra1 or, as loading control, gapdh speciﬁc
primers. (B) LN229 glioblastoma cells were either not incubated or pre-incubated for
1 h with the transcription blocking agent actinomycin D (ActD). Thereafter cells were ex-
posed to 100 μM ACNU or kept unexposed. 6 h later total RNA was isolated and semi-
quantitative RT-PCR was performed using fra1 or, as loading control, gapdh speciﬁc
primers. (C) LN229 cells were exposed to 50 μM ACNU for the indicated times. Whole
cell extractswere prepared and subjected toWesternblot analysis. Themembranewas in-
cubated with FRA1 speciﬁc antibody or, as loading control, with β-Actin speciﬁc antibody.
(D) LN229 cells were exposed to 50 μM ACNU for the indicated times. Nuclear extracts
were prepared and subjected to Western blot analysis. The membrane was incubated
with antibodies against c-Jun, phospho-c-Jun (c-Jun-Ser73), FRA1 or, as loading control,
with β-Actin speciﬁc antibody. (E) LN229 cells were pre-incubated for 1 h with a speciﬁc
inhibitor for JNK1/2/3 (SP600125), p38K (SB103580) and MEK1/2 (U0126) and 8 h or
24 h after treatment with 50 μM ACNU, whole cell extracts were prepared and subjected
toWestern blot analysis. Themembranewas incubatedwith FRA1 and, as loading control,
with ERK2 speciﬁc antibodies.
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nearly completely abrogated ACNU-induced FRA1 expression after
24 h. In contrast, inhibition of the JNK activity by the JNK1/2/3 inhib-
itor SP600125 had no impact on FRA1 expression. The data suggest
that p38K and ERK1/2 are involved in FRA1 upregulation following
ACNU treatment.
3.2. Silencing of FRA1 confers sensitivity to ACNU
To analyzewhether induction of FRA1 impacts the sensitivity of glio-
blastoma cells to ACNU, FRA1 was transiently or stably down-regulated
via siRNA and shRNA, respectively. Transient downregulation of FRA1
using siRNA was veriﬁed on protein level. Thus a strongly reduced
expression of FRA1 was observed in ACNU-exposed LN229 cells 48
and 72 h after siRNA transfection (Fig. 2A). To compare parental
LN229 and FRA1-depleted LN229 cells as to their sensitivity to ACNU,cell death was measured by ﬂow cytometry as Sub-G1 fraction
(Fig. 2B). Cell death occurred at a signiﬁcant higher frequency in
LN229 cells transfected with FRA1-siRNA than in those transfected
with a nonsense siRNA (Fig. 2B). To substantiate the data, we
established stable FRA1 knockdown cells. The most efﬁcient down-
regulation was observed in the clone sh-10 (Fig. 2C). This clone was
designated LN229-FRA1-shRNA and used for further experiments. Be-
sides basal expression, also ACNU-induced FRA1 induction was clearly
reduced in the knockdown cells in comparison to the vector-only con-
trol (LN229-vec) (Fig. 2D). Using these cell lines we again measured
cell death (Sub-G1 fraction) as a function of dose (5–100 μM ACNU)
96 h after ACNU treatment (Fig. 2E). Also in these experiments, cell
death occurred at a higher frequency in FRA1-depleted LN229-FRA1-
shRNA cells. However, the increased sensitivity of LN229-FRA1-shRNA
cells was only observed at dose levels above 50 μM ACNU (Fig. 2E), in-
dicating a threshold for the protective effect of FRA1. Overall, the data
suggest a functional role of FRA1 induction in the protection against
the anticancer drug ACNU. To substantiate the ﬁndings obtained with
LN229 cells, additional experiments were performed with the glioma
lines U87 and U138, which were transfected with FRA1 siRNA
(Fig. 2F). In these cells, cell death (Sub-G1 fraction) was measured
96 h upon exposure to 50 μM ACNU (Fig. 2G). Also in U87 and U138
cells, death occurred at a higher frequency upon FRA1 knockdown,
suggesting that the effect of FRA1 on ACNU-mediated cell death in
glioma cells is not limited to a speciﬁc cell line, but represents a more
general effect.3.3. FRA1-mediated resistance to ACNU is independent of FasL regulation
AP‐1 dependent gene regulation has been shown to be important
for both apoptosis and DNA repair. AP-1 regulates fasL, an important
factor of the extrinsic apoptotic pathway [19], as well as the DNA re-
pair genes ercc1, xpf and xpg [6,7,20]. To analyze the effect of FRA1
downregulation on ACNU-induced activation of AP‐1, electromobility
shift assays (EMSA) were performed using radioactively labeled oli-
gonucleotides harboring the AP-1 binding site of the collagenase 1
(matrix metalloproteinase-1, mmp1) promoter. The oligonucleotides
were incubated with nuclear extracts obtained from LN229-vec and
LN229-FRA1-sh cells, either untreated or treated with 50 μM ACNU
for different times. As shown in Fig. 3A, a time-dependent induction
of AP-1 binding activity was observed using the mmp1 AP-1 binding
site. The AP-1 binding activity was at maximum 16–24 h after ACNU
exposure. In LN229-FRA1-sh cells a strong reduction of the AP-1 bind-
ing activity was observed, indicating that reduction of FRA1 protein
expression directly translates into reduced AP-1 binding activity. To
verify that FRA1 is a component of the AP-1 complex upon ACNU ex-
posure, supershift experiments were performed. As shown in Fig. 3B,
FRA1 and its binding partner c-Jun are present in the AP-1 complex in
LN229-vec cells, 24 h after ACNU exposure, however in LN229-FRA1-
shRNA cells only c-Jun can be detected.
One of themost important AP-1 target genes encodes the Fas ligand
(fasL). To analyze whether reduced AP-1 activity leads to a differential
regulation of fasL mRNA upon ACNU treatment, semi-quantitative
RT-PCR and real-time RT-PCR were performed. A slight induction of
fasL was observed 0–24 h after treatment in LN229-vec, but not in
LN229-FRA1-shRNA cells, as determined by semi-quantitative RT-PCR
(Fig. 3C). Real-time RT-PCR showed a two times higher basal expression
in LN229-vec cells and a comparable induction of fasL mRNA upon
ACNU exposure in both LN229-vec and LN229-FRA1-shRNA cells
(Fig. 3D). In addition, a slightly higher expression of the membrane-
bound and the soluble FasL protein was observed in LN229-vec com-
pared to LN229-FRA1-shRNA cells (Fig. 3E), indicating that FRA1 down-
regulation only marginally impacts the regulation of FasL. In contrast to
fasLmRNA, the mRNA coding for the Fas receptor (fasR) was increased
in both cell lines following ACNU treatment (Fig. 3C).
- + - + - + FRA1-siRNA
FRA1
ß-Actin
24 48 72 time (h)
FRA1
ß-Actin
A
D
con vec sh-5 sh-10 sh-12
FRA1
ß-Actin
E
con 25 50 con 25 50 [µM]
C
0
20
40
60
80
con ns
siRNA
FRA1
siRNA
ns
siRNA
ACNU
FRA1
siRNA
ACNU
B
LN229-
Fra1-shRNALN229-vec
0
10
20
30
40
50
60
con
LN229-vec
LN229-FRA1-sh
Su
b-
G
1 
(%
)
Su
b-
G
1 
(%
)
5 10 25 50 100
**
*
**
- + - + FRA1-siRNA
FRA1
ß-Actin
U87 U138
F G
In
du
ce
d 
Su
b-
G
1 
(%
)
0
5
10
15
20
25
30
35
ACNU ns FRA1 ns FRA1
siRNAsiRNAsiRNAsiRNA
U87 U138
*
*
ACNU
ACNU[µM]
Fig. 2. Effect of FRA1 knockdown on sensitivity to ACNU. (A) FRA1 expression was analyzed by the use of speciﬁc antibodies in LN229 cells, 24 to 72 h after transfection with FRA1
siRNA. To analyze the effect of the downmodulation on the ACNU-induced FRA1 level, cells were exposed to 50 μM ACNU 6 h before harvest. (B) To monitor the impact of FRA1
knockdown on sensitivity to ACNU, LN229 cells were transfected with FRA1 speciﬁc siRNA (FRA1-si) or nonsense‐siRNA (ns-si). 24 h later, cells were exposed to 25 μM ACNU
and incubated for 96 h. Cells were stained with PI and the sub-G1 fraction was determined by ﬂow cytometry. (*pb0.05). (C) FRA1 expression was analyzed by the use of speciﬁc
antibodies in different LN229 clones, stably transfected with FRA1-shRNA. (D) FRA1 expression was analyzed by the use of speciﬁc antibodies in LN229 cells stably transfected with
FRA1 speciﬁc shRNA (LN229-FRA1-shRNA=sh10) or a vector only clone (LN229-vec) 24 h after exposure to 25 or 50 μM ACNU. (E) LN229-FRA1-shRNA cells and LN229-vec cells
were exposed to different ACNU doses and incubated for 96 h. Cells were stained with PI and the sub-G1 fraction was determined by ﬂow cytometry. (*pb0.05, **pb0.01). (F) FRA1
expression was analyzed by the use of speciﬁc antibodies in U87 und U138 cells, 24 h after transfection with FRA1 siRNA. (G) U87 and U138 cells were transfected with FRA1
speciﬁc siRNA (FRA1-si) or nonsense‐siRNA (ns-si). 24 h later, cells were exposed to 50 μM ACNU and incubated for 96 h. Cells were stained with PI and the Sub-G1 fraction
was determined by ﬂow cytometry. (*pb0.05).
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AP-1-associated regulation of DNA repair
Several proteins of the NER (nucleotide excision repair) pathway
have been described to be transcriptionally regulated, e.g. XPF and
XPG, which are induced by AP-1 upon exposure of ﬁbroblasts to
UV-light [7]. Little is known, however, about the regulation of the
corresponding genes in tumor cells after exposure to anticancer
drugs. To analyze the regulation of these genes upon ACNU treatment,
semi-quantitative RT-PCR was performed. No alterations in the ex-
pression of xpf mRNA were observed, neither in LN229-vec nor inLN229-FRA1-shRNA cells (Fig. 4A). For ercc1 a slight induction was
observed 16–48 h upon ACNU treatment in LN229-vec but not in
LN229-FRA1-shRNA cells (Fig. 4A). However, no differences in the
expression were observed on protein level (Fig. 4B).
To measure the impact of FRA1 downmodulation on DNA repair,
DNA damage was determined using the alkaline comet assay, which
detects mostly DNA single-strand breaks. Additionally, a modiﬁed
alkaline comet assay, which detects DNA crosslinks [21], was per-
formed. To this end, LN229 cells were transfected with FRA1-siRNA
and 24 h later exposed to 25 or 50 μM ACNU. At different time points,
cells were collected and subjected to the comet assay. As shown in
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Fig. 3. Impact of FRA1 down-modulation on AP-1 activity and FasL expression. (A) LN229-vec cells and LN229-FRA1-shRNA cells were exposed to 50 μM ACNU and harvested at
indicated time points. Nuclear extracts were isolated and incubated with radioactively labeled oligonucleotides containing the AP-1 binding site of the collagenase promoter
(mmp1). The binding of AP-1 was visualized by EMSA and the speciﬁc complex is indicated by an arrow. (B) EMSA supershift assay: The presence of c-Jun and FRA1 in the AP-1
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(D) 24 h after exposure, total RNA was isolated and real-time RT-PCR was performed using fasL speciﬁc primers. Expression was normalized on gapdh and β-actin, and the fasL
expression of untreated LN229-vec cells was set to one. (E) LN229-vec and LN229-FRA1-shRNA cells were exposed to 50 μM ACNU for the indicated times. Protein extracts were
prepared and subjected to Western blot analysis. The membrane was incubated with FasL speciﬁc antibody or, as loading control, with β-Actin speciﬁc antibody.
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breaks (Fig. 5A) or crosslinks (Fig. 5B) were observed between FRA1
expressing and FRA1 downmodulated cells.
Next we analyzed the generation of DNA double-strand breaks
(DSB) by measuring the phosphorylation of H2AX (γH2AX), a sensi-
tive marker for DSB. A strong time-dependent phosphorylation of
H2AX occurred following ACNU treatment, which was comparable
in FRA1 proﬁcient cells and cells transfected with FRA1-siRNA
(Fig. 5C) as well as in LN229-vec and LN229-FRA1-shRNA cells
(Fig. 5D). The data indicate that FRA1 neither impacts DNA damage
formation nor repair.
3.5. FRA1 mediated resistance to ACNU is associated with delayed cell
cycle progression
It was previously shown that FRA1 confers sensitivity to cisplatin by
its effect on cell cycle checkpoints. Thus, knockdown of FRA1 resulted ina reduced S-phase arrest, which was signaled through modulation of
the CHK1–Cdk2 pathway [12]. To analyze the effect of FRA1 on cell
cycle checkpoints upon exposure of glioblastoma cells to ACNU the
cell cycle distribution was analyzed via ﬂow cytometry 96 h after expo-
sure (Fig. 6A). Following exposure to ACNU, a strong accumulation of
cells in the G2-phase was observed. The amount of LN229-vec cells in
the G2-phase increased from approximately 20% in untreated cells to
80% in cells exposed to 50 μM ACNU. In untreated LN229-FRA1-shRNA
cells the cell cycle distribution was similar to untreated LN229-vec
cells, whereas upon exposure to 50 μM ACNU only 50% of the cells
were arrested in G2. The amount of cells either in G1 and S-Phase was
increased to 25%. The data indicate that at this dose the FRA1 knock-
down leads to a reduced G2-phase arrest or to an accumulation of the
cells in the G1/S-phase before entering the G2-phase. Similar results
were obtained in U87 and U138 cells (Fig. 6B). In both cell lines, knock-
down of FRA1 leads to an increased S-phase population and a decrease
of cells in the G2 phase.
gapdh
ercc1
xpf
con 8 16 24 48time(h)con 8 16 24 48
LN229-FRA1-shRNALN229-vec
A
time(h)con 24 48 72 con 24 48 72
XPF
ß-Actin
LN229-FRA1-shRNALN229-vec
ERCC1
B
Fig. 4. Impact of FRA1 down-modulation on the expression of NER genes. (A) LN229-
vec and LN229-FRA1-shRNA cells were exposed to 50 μM ACNU. At different time
points after exposure, total RNA was isolated and semi-quantitative RT-PCR was per-
formed using xpf, ercc1 or, as loading control, gapdh speciﬁc primers. (B) LN229-vec
and LN229-FRA1-shRNA cells were exposed to 50 μM ACNU for the indicated time
points. Protein extracts were prepared and subjected to Western blot analysis. The
membrane was incubated with XPF or ERCC1 speciﬁc antibodies. β-Actin was used as
loading control.
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mediated via the ATR–CHK1–Cdc25c axis [1]. To investigate the activa-
tion of this DNA damage response cascade, the phosphorylation of the
serine/threonine-protein kinase CHK1 was analyzed using speciﬁc anti-
bodies (Fig. 6C and D). In both LN229-FRA1-shRNA and LN229-vec cells,
similar CHK1 phosphorylation was observed 24 h after ACNU exposure
(Fig. 6C). However, additional 24 h later, phosphorylated CHK1, was
only detectable in LN229-vec cells. In LN229-FRA1-shRNA cells not
only the expression of the phosphorylated but also of the non-
phosphorylated CHK1 protein was strongly reduced, which could attri-
bute to the observed reduced accumulation of the cells in the G2/M
phase. To substantiate our data concerning the reduced CHK1 activation
in the absence of FRA1 we further utilized siRNA mediated knockdown
of FRA1 in U87 and U138 cells. Similar to the data obtained in LN229
cells, knockdown of FRA1 resulted in a reduced phosphorylation of
CHK1 48 h after ACNU exposure in both U87 and U138 cells (Fig. 6D).
4. Discussion
The dimeric transcription factor AP-1 is involved in the regulation of
several cellular keymechanisms like angiogenesis, apoptosis, differenti-
ation, hypoxia, invasion, metastasis and proliferation [4]. Furthermore,
AP-1 dimers containing c-Fos are involved in the regulation of several
DNA repair genes. Thus the UV-induced upregulation of the DNA repair
genes trex1, xpf and xpg is mediated by c-Fos, which stimulates DNA re-
pair activity and protects against genotoxin-induced cell death [5-7].12 24 48
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(FRA2). Contrary to c-Fos, FRA1 has no transactivation domain and in
glioblastoma cells its transcriptional activity is dependent on its interac-
tion with JunB [22]. In glioblastoma, FRA1 has been suggested to be in-
volved in the maintenance and progression of the disease [11].
Here, we analyzed the role of FRA1 in the sensitivity of the glioblas-
toma cell line LN229 to the anticancer drug ACNU that acts similar to
BCNU (carmustine), CCNU (lomustine), MeCCNU (semustine) and
fotemustine [23]. These drugs are used in the therapy of malignant gli-
oma, metastatic melanoma and other tumors. We show that upon
ACNU exposure FRA1 is transcriptionally induced within 8–16 h. Tran-
scriptional activation of FRA1 was described for different mitogens,
but not yet for genotoxicants, and was shown to be mediated via
serum and TPA response elements [24]. Upon ACNU exposure, induc-
tion of FRA1 mRNA is accompanied by a strong increase in the
corresponding protein level. FRA1 is additionally post-translationally
modiﬁed by members of the MAPK cascade since inhibition of p38K
and ERK2 led to a strong decline in FRA1 protein expression, which is
in linewith previously published data on the regulation of FRA1 [25,26].
Using transient (siRNA) and stable (shRNA) knockdown strate-
gies, we showed that FRA1 is involved in the protection against
ACNU-induced cytotoxicity. Downregulation of FRA1 resulted in de-
creased AP-1 binding activity as measured by EMSA using the mmp1
AP-1-binding site. However, in contrast to data obtained in melanoma
cells where FRA1 is important for the basal expression of mmp1 [27],
the downregulation of FRA1 in glioblastoma cells did not change the
basal AP-1 binding activity to mmp1 speciﬁc AP-1 binding site, but
rather reduced the ACNU-induced AP-1 binding activity.One of the most prominent targets of AP-1 is the gene encoding
the Fas ligand (fasL) [19,28]. Fas ligand binds to the Fas receptor
and thereby activates the extrinsic apoptotic pathway [29,30], leading
to cell death. Induction of the fasL gene is a key component of the
apoptotic pathway, which is mediated via the SAPK/JNK signaling
cascade [19,31] and activation of AP-1. Whereas the participation of
c-Jun, ATF2 and FosB in the induction of fasL is well established
[19,32,33], the role of c-Fos and FRA1 is not clear. Previously we
showed that upon UV exposure, c-Fos is not involved in the induction
of FasL [34]. Upon ACNU exposure of LN229 cells induction of fasL
mRNA was observed, which was not the case in cells knockdown for
FRA1. Concomitant with fasL mRNA a slightly higher expression of
membrane-bound and soluble FasL protein was observed in FRA1 ex-
pressing cells, indicating that FRA1 is involved in the transcriptional
regulation of fasL. However, since FRA1 knockdown cells that show
no fasL induction and lower FasL expression, are more sensitive to
ACNU it is pertinent to posit that the protective effect of FRA1 is not
related to the regulation of the FasL. It appears that FRA1 regulates
in addition to the FasL another function that neutralizes FasL
upregulation, thus exerting strong killing protection.
Besides the fasL, several DNA repair genes involved in the NER
pathway like ercc1, xpf, and xpg are regulated by AP-1 [6,7,20]. NER
and especially the proteins ERCC1 and XPF are involved in the repair
of mono-adducts and crosslinks induced by chloroethylating antican-
cer drugs [35]. Therefore, differential regulation of NER genes could
attribute to the observed sensitizing effect of FRA1 knockdown. How-
ever, opposite to data obtained in ﬁbroblasts following UV exposure
[6,7], ACNU did not lead to the induction of xpf in glioblastoma cells.
1206 R. Meise et al. / Biochimica et Biophysica Acta 1823 (2012) 1199–1207For ercc1 a slight induction was observed in the FRA1 proﬁcient,
but not the FRA1 downmodulated cells. However, similar to fasL,
the induction of ercc1 mRNA did not lead to a signiﬁcant change in
the expression level of the corresponding ERCC1 protein. Also in the
case of XPF no ACNU-induced upregulation of the protein was
observed. To further analyze the effect of FRA1 downmodulation
on DNA repair, the formation and repair of SSB, DSB and crosslinks
was analyzed, showing in all cases no differences between FRA1
proﬁcient and FRA1 downregulated cells, again indicating that the
effect of FRA1 on ACNU-triggered toxicity is not based on modulation
of DNA repair.
In contrast to the missing effect of FRA1 on the regulation of DNA
repair we observed that FRA1 modulates cell cycle progression upon
ACNU exposure. Thus, in FRA1 downregulated cells sensitization to
ACNU was accompanied by a reduced G2 arrest. An important factor
in the regulation of the G2/M checkpoint is CHK1. This kinase phos-
phorylates Cdc25c which induces binding of Cdc25c to the 14-3-3
protein [36,37]. Within this complex, Cdc25c is transported out of
the nucleus and therefore unable to dephosphorylate/activate
Cdk1–CyclinB, which ﬁnally leads to G2/M arrest [38]. In our experi-
ments, we observed a comparable initial activation of CHK1 24 h
after exposure of cells to ACNU. However 48 h after exposure, phos-
phorylated CHK1 was observed only in FRA1 proﬁcient but not FRA1
downregulated cells. From these data we conclude that reduced
CHK1 phosphorylation observed in FRA1 downregulated cells leads
to an abrogation of the G2/M cell cycle check point. Interestingly a de-
creased phosphorylation of CHK1 was also observed upon cisplatin
treatment of glioma cells downregulated for another member of the
AP-1 family, namely ATF3 [12]. Also in this case, downregulation of
ATF3 conferred sensitivity to anticancer drug treatment. The abrogat-
ed G2/M arrest observed in FRA1 downregulated cells may lead to
progression of cells through mitosis before the DNA damage is
repaired, ﬁnally leading to cell death in the subsequent cell cycle.
What are the clinical implications? The treatment of gliomas suffers
from poor response of the tumor and, therefore, most patients succumb
to the disease. Only a few factors that determine resistance of glioblas-
toma cells to chloroethylating anticancer drugs have been identiﬁed
so far. One is the DNA repair proteinMGMT, which removes chloroethyl
groups from the O6-position of guanine ([23,39]). In addition, the FA
pathway, especially FANCD1/BRCA2 confers glioma resistance to BCNU
[40] andACNU [41]. It has also been shown that p53mediates resistance
to chloroethylating agents, by induction of the nucleotide excision re-
pair proteins DDB2 and XPC [42]. Our data suggests FRA1 to be a novel
player in the resistance of glioma cells to chloroethylating anticancer
drugs. A concept in tumor chemotherapy rests on the use of inhibitors
of DNA damage signaling and repair, either as monotherapy or in com-
bination with anticancer drugs [43]. However, inhibition of transcrip-
tion factors like FRA1 seems not to be feasible due to their broad
involvement in different cellular functions. Our data indicate that the
protective effect of FRA1 is associated with CHK1. CHK1 inhibitors like
UCN-01 or XL844 are used already in the clinic in phase I and II studies
alone or in combination with anticancer drugs like topoisomerase in-
hibitors [44]. Therefore, inhibition of CHK1 seems to be a reasonable
strategy to sensitize glioma cells to ACNU.Acknowledgements
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